Sharma Vinay K, Dellinger R Phillip
Medical Intensive Care Unit, The Graduate Hospital & Clinical Assistant Professor of Medicine, Drexel University College of Medicine, Pepper Pavilion, Suite 607, 1800 Lombard Street, Philadelphia, PA 19144, USA.
Expert Rev Anti Infect Ther. 2006 Jun;4(3):395-403. doi: 10.1586/14787210.4.3.395.
Despite significant advances in the understanding of the pathophysiology of sepsis, severe sepsis and septic shock continue to be associated with high morbidity and mortality. Eradication of infection, with appropriate antibiotics and source control, remains the cornerstone of sepsis management, but does not ensure survival. Aggressive supportive care, such as fluid resuscitation, vasoactive agents or mechanical ventilation, is often required. With the exception of drotrecogin alfa, attempts to modulate the inflammatory response in sepsis have generally been unsuccessful. Early goal-directed therapy targeting adequate central venous oxygen saturation appears to improve outcome. Recently, there has been renewed interest in the use of corticosteroids, not as anti-inflammatory agents, but as replacement therapy. There is also some evidence to suggest that tight glucose control may improve outcome in these patients.
尽管在脓毒症病理生理学的理解方面取得了重大进展,但严重脓毒症和脓毒性休克仍然与高发病率和死亡率相关。使用适当的抗生素和控制感染源来根除感染,仍然是脓毒症管理的基石,但并不能确保患者存活。通常需要积极的支持治疗,如液体复苏、血管活性药物或机械通气。除了活化蛋白C,调节脓毒症炎症反应的尝试总体上并不成功。以达到足够的中心静脉血氧饱和度为目标的早期目标导向治疗似乎可以改善预后。最近,人们对使用皮质类固醇重新产生了兴趣,不是将其作为抗炎药物,而是作为替代疗法。也有一些证据表明,严格控制血糖可能会改善这些患者的预后。